E
DNLI icon

Ergoteles’s Denali Therapeutics DNLI Stock Holding History

Ergoteles’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,788
Closed -$318K – 267
2023
Q2 		$318K Sell
10,788
-26,703
-71% -$751K 0.02% 752
2023
Q1 		$864K Buy
+37,491
New +$1.03M 0.03% 550
2022
Q2 		– Sell
-6,693
Closed -$215K – 1715
2022
Q1 		$215K Buy
+6,693
New +$230K 0.01% 961
2021
Q2 		– Sell
-10,300
Closed -$588K – 1531
2021
Q1 		$588K Buy
+10,300
New +$690K 0.02% 452

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Ergoteles's DNLI Position: Q3 2023 in Review

Ergoteles sold out of Denali Therapeutics (DNLI) in Q3 2023, closing a stake of 10,788 shares — an estimated $318K sold.

Ergoteles first reported a position in DNLI in Q1 2021 and held it in 4 quarters. The position peaked at $864K in Q1 2023. 194 funds tracked by Wall St. Rank hold DNLI as of Q3 2023.

  • Ergoteles reported no remaining Denali Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 10,788 Denali Therapeutics shares in Q3 2023, an estimated $318K.
  • Ergoteles first reported a position in Denali Therapeutics in Q1 2021 and held it in 4 quarters.
  • Ergoteles's Denali Therapeutics position peaked at $864K in Q1 2023.
  • 194 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.